IκBα promoter polymorphisms in patients with Behçet's disease

Disease Markers

Volumn 28, Issue 1, 2010, Pages 55-62

  Hung, Yu Hung ^a   Wu, Cheng Chin ^b   Ou, Tsan Teng ^b   Lin, Chia Hui ^b   Li, Ruei Nian ^c   Lin, Yu Chih ^b   Tsai, Wen Chan ^b   Liu, Hong Wen ^b   Yen, Jeng Hsien ^a,b,c  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Beh et's disease; I B ; NFkB inhibitor; Polymorphisms

Indexed keywords

I KAPPA B ALPHA; I KAPPA B; NF KAPPAB INHIBITOR ALPHA; NF-KAPPAB INHIBITOR ALPHA;

ADULT; ARTICLE; BEHCET DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SKIN DEFECT; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; MIDDLE AGED; PATHOLOGY; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN;

ADULT; BEHCET SYNDROME; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HUMANS; I-KAPPA B PROTEINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SKIN;

EID: 77249172154     PISSN: 02780240     EISSN: None     Source Type: Journal    
DOI: 10.3233/DMA-2010-0684     Document Type: Article

References (47)

1. S. Ohno, M. Ohguchi, S. Hirose, H. Matsuda, A.Wakisaka and M. Aizawa, Close association of HLA-Bw51 with Behcet's disease, Arch Ophthalmol 100 (1982), 1455-1458.
2. N. Mizuki, M. Ota, Y. Katsuyama, K. Yabuki, H. Ando, T. Shiina, E. Nomura, K. Onari, S. Ohno and H. Inoko, HLA-B*51 allele analysis by the PCR-SBT method and a strong association of HLA-B*5101 with Japanese patients with Behcet's disease, Tissue Antigens 58 (2001), 181-184.
3. S. Hirohata and H. Kikuchi, Behcet's disease, Arthritis Res Ther 5 (2003), 139-146.
4. R. Gunesacar, E. Erken, B. Bozkurt, H.T. Ozer, S. Dinkci, E.G. Erken and Z. Ozbalkan, Analysis of CD28 and CTLA-4 gene polymorphisms in Turkish patients with Behcet's disease, Int J Immunogenet 34 (2007), 45-49.
5. J. Karasneh, A.H. Hajeer, J. Barrett, W.E. Ollier, M. Thornhill and A. Gul, Association of specific interleukin 1 gene cluster polymorphisms with increased susceptibility for Behcet's disease, Rheumatology (Oxford) 42 (2003), 860-864.
6. A. Meguro, M. Ota, Y. Katsuyama, A. Oka, S. Ohno, H. Inoko and N. Mizuki, Association of the toll-like receptor 4 gene polymorphisms with Behcet's disease, Ann Rheum Dis 67 (2008), 725-727.
7. K. Durrani and G.N. Papaliodis, The genetics of Adamantiades-Behcet's disease, Semin Ophthalmol 23 (2008), 73-79.
8. J.H. Yen, W.C. Tsai, C.H. Lin, T.T. Ou, C.J. Hu and H.W. Liu, Cytochrome P450 1A1 and manganese superoxide dismutase gene polymorphisms in Behcet's disease, J Rheumatol 31 (2004), 736-740.
9. I. Krause and A. Weinberger, Behcet's disease, Curr Opin Rheumatol 20 (2008), 82-87.
10. Y.J. Lee, S.W. Kang, J.J. Park, Y.D. Bae, E.Y. Lee, E.B. Lee and Y.W. Song, Interleukin-18 promoter polymorphisms in patients with Behcet's disease, Hum Immunol 67 (2006), 812-818.
11. T. Ahmad, G.R. Wallace, T. James, M. Neville, M. Bunce, K. Mulcahy-Hawes, A. Armuzzi, J. Crawshaw, F. Fortune, R. Walton, M.R. Stanford, K.I. Welsh, S.E. Marshall and D.P. Jewell, Mapping the HLA association in Behcet's disease: a role for tumor necrosis factor polymorphisms? Arthritis Rheum 48 (2003), 807-813.
12. K. Nakao, Y. Isashiki, S. Sonoda, E. Uchino, Y. Shimonagano and T. Sakamoto, Nitric oxide synthase and superoxide dismutase gene polymorphisms in Behcet disease, Arch Ophthalmol 125 (2007), 246-251.
13. J.A. Karasneh, A.H. Hajeer, A. Silman, J. Worthington, W.E. Ollier and A. Gul, Polymorphisms in the endothelial nitric oxide synthase gene are associated with Behcet's disease, Rheumatology (Oxford) 44 (2005), 614-617.
14. J. Karasneh, A. Gul, W.E. Ollier, A.J. Silman and J. Worthington, Whole-genome screening for susceptibility genes in multicase families with Behcet's disease, Arthritis Rheum 52 (2005), 1836-1842.
15. K. Hamzaoui, A. Hamzaoui, I. Ghorbel, M. Khanfir and H. Houman, Levels of IL-15 in serum and cerebrospinal fluid of patients with Behcet's disease, Scand J Immunol 64 (2006), 655-660.
16. U. Musabak, S. Pay, H. Erdem, I. Simsek, A. Pekel, A. Dinc and A. Sengul, Serum interleukin-18 levels in patients with Behcet's disease. Is its expression associated with disease activity or clinical presentations? Rheumatol Int 26 (2006), 545-550.
17. H. Yanagihori, N. Oyama, K. Nakamura, N. Mizuki, K. Oguma and F. Kaneko, Role of IL-12B promoter polymorphism in Adamantiades-Behcet's disease susceptibility: An involvement of Th1 immunoreactivity against Streptococcus Sanguinis antigen, J Invest Dermatol 126 (2006), 1534-1540.
18. A. Kulaber, I. Tugal-Tutkun, S.P. Yentur, G. Akman- Demir, F. Kaneko, A. Gul and G. Saruhan-Direskeneli, Proinflammatory cellular immune response in Behcet's disease, Rheumatol Int 27 (2007), 1113-1118.
19. P.J. Barnes and M. Karin, Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases, N Engl J Med 336 (1997), 1066-1071.
20. P.A. Baeuerle, Pro-inflammatory signaling: last pieces in the NF-kappaB puzzle? Curr Biol 8 (1998), R19-R22.
21. P.P. Tak and G.S. Firestein, NF-kappaB: a key role in inflammatory diseases, J Clin Invest 107 (2001), 7-11.
22. S. Castro-Alcaraz, V. Miskolci, B. Kalasapudi, D. Davidson and I.Vancurova, NF-kappaBregulation in human neutrophils by nuclear I kappa B alpha: correlation to apoptosis, J Immunol 169 (2002), 3947-3953.
23. E. Dale, M. Davis and D.L. Faustman, A role for transcription factor NF-kappaB in autoimmunity: possible interactions of genes, sex, and the immune response, Adv Physiol Educ 30 (2006), 152-158.
24. M.J. May and S. Ghosh, Rel/NF-kappa B and I kappa B proteins: an overview, Semin Cancer Biol 8 (1997), 63-73.
25. S.T. Whiteside and A. Israel, I kappa B proteins: structure, function and regulation, Semin Cancer Biol 8 (1997), 75-82.
26. N. Mozzato-Chamay, E.L. Corbett, R.L. Bailey, D.C. Mabey, J. Raynes and D.J. Conway, Polymorphisms in the IkappaBalpha promoter region and risk of diseases involving inflammation and fibrosis, Genes Immun 2 (2001), 153-155.
27. F. Emmerich, M. Meiser, M. Hummel, G. Demel, H.D. Foss, F. Jundt, S. Mathas, D. Krappmann, C. Scheidereit, H. Stein and B. Dorken, Overexpression of I kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells, Blood 94 (1999), 3129-3134.
28. C.H. Lin, T.T. Ou, C.C. Wu, W.C. Tsai, H.W. Liu and J.H. Yen, IkappaBalpha promoter polymorphisms in patients with rheumatoid arthritis, Int J Immunogenet 34 (2007), 51-54.
29. C.H. Lin, S.C. Wang, T.T. Ou, R.N. Li, W.C. Tsai, H.W. Liu and J.H. Yen, IkappaBalpha Promoter Polymorphisms in Patients with Systemic Lupus Erythematosus, J Clin Immunol 11 (2007), 11.
30. Criteria for diagnosis of Behcet's disease. International Study Group for Behcet's Disease, Lancet 335 (1990), 1078-1080.
31. M. Todaro, M. Zerilli, G. Triolo, F. Iovino, M. Patti, A. Accardo-Palumbo, F. di Gaudio, M.C. Turco, A. Petrella, R. de Maria and G. Stassi, NF-kappaB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins, Arthritis Rheum 52 (2005), 2179-2191.
32. A. Kawakami and K. Eguchi, Involvement of apoptotic cell death in autoimmune diseases, Med Electron Microsc 35 (2002), 1-8.
33. F. Arenzana-Seisdedos, J. Thompson, M.S. Rodriguez, F. Bachelerie, D. Thomas and R.T. Hay, Inducible nuclear expression of newly synthesized I kappa B alpha negatively regulates DNA-binding and transcriptional activities of NF-kappa B, Mol Cell Biol 15 (1995), 2689-2696.
34. P. Turpin, R.T. Hay and C. Dargemont, Characterization of IkappaBalpha nuclear import pathway, J Biol Chem 274 (1999), 6804-6812.
35. F. Arenzana-Seisdedos, P. Turpin, M. Rodriguez, D. Thomas, R.T. Hay, J.L. Virelizier and C. Dargemont, Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm, J Cell Sci 110 ( Pt 3) (1997), 369-378.
36. M.K. Ernst, L.L. Dunn and N.R. Rice, The PEST-like sequence of I kappa B alpha is responsible for inhibition of DNA binding but not for cytoplasmic retention of c-Rel or RelA homodimers, Mol Cell Biol 15 (1995), 872-882.
37. C.Y. Ito, A.G. Kazantsev and A.S. Baldwin, Jr., Three NFkappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha, Nucleic Acids Res 22 (1994), 3787-3792.
38. T.T. Ou, C.H. Lin, Y.C. Lin, R.N. Li,W.C. Tsai, H.W. Liu and J.H. Yen, IkappaBalpha promoter polymorphisms in patients with primary Sjogren's syndrome, J Clin Immunol 28 (2008), 440-444.
39. B. Miterski, S. Bohringer, W. Klein, E. Sindern, M. Haupts, S. Schimrigk and J.T. Epplen, Inhibitors in the NFkappaB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations, Genes Immun 3 (2002), 211-219.
40. W. Klein, A. Tromm, C. Folwaczny, M. Hagedorn, N. Duerig, J.T. Epplen, W.H. Schmiegel and T. Griga, A polymorphism of the NFKBIA gene is associated with Crohn's disease pa tients lacking a predisposing allele of the CARD15 gene, Int J Colorectal Dis 19 (2004), 153-156.
41. K. Katarina, P. Daniela, N. Peter, R. Marianna, C. Pavlina, P. Stepanka, L. Jan, T. Ludmila, A. Michal and C. Marie, HLA, NFKB1 and NFKBIA gene polymorphism profile in autoimmune diabetes mellitus patients, Exp Clin Endocrinol Diabetes 115 (2007), 124-129.
42. J. Gao, D. Pfeifer, L.J. He, F. Qiao, Z. Zhang, G. Arbman, Z.L. Wang, C.R. Jia, J. Carstensen and X.F. Sun, Association of NFKBIA polymorphism with colorectal cancer risk and prognosis in Swedish and Chinese populations, Scand J Gastroenterol 42 (2007), 345-350.
43. X.F. Sun and H. Zhang, NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases, Histol Histopathol 22 (2007), 1387-1398.
44. A. Abdallah, H. Sato, J.C. Grutters, S. Veeraraghavan, P.A. Lympany, H.J. Ruven, J.M. van den Bosch, A.U. Wells, R.M. du Bois and K.I. Welsh, Inhibitor kappa B-alpha (IkappaBalpha) promoter polymorphisms in UK and Dutch sarcoidosis, Genes Immun 4 (2003), 450-454.
45. A.A. Beg, W.C. Sha, R.T. Bronson and D. Baltimore, Constitutive NF-kappa B activation, enhanced granulopoiesis, and neonatal lethality in I kappa B alpha-deficient mice, Genes Dev 9 (1995), 2736-2746.
46. J.F. Klement, N.R. Rice, B.D. Car, S.J. Abbondanzo, G.D. Powers, P.H. Bhatt, C.H. Chen, C.A. Rosen and C.L. Stewart, IkappaBalpha deficiency results in a sustained NF-kappaB response and severe widespread dermatitis in mice, Mol Cell Biol 16 (1996), 2341-2349.
47. C. Butt, S. Sun, L. Peddle, C. Greenwood, S. Hamilton, D. Gladman and P. Rahman, Association of nuclear factorkappaB in psoriatic arthritis, J Rheumatol 32 (2005), 1742-1744.